Menu
Search

Tag archives: ad

Pfizer, the global biopharmaceutical company, held a launch ceremony for Cibinqo – an oral, once-daily highly selective JAK1 (Janus kinase 1) inhibitor, for treating adult patients with moderate-to-severe atopic dermatitis -- in China on Sunday. Launch ceremonies for this product were held in 10 cities, including Beijing, Shanghai and Guangzhou, across China. Jean-Christophe Pointeau, president of China Pfizer Biopharmaceutical Group, said that Cibinqo is the group"s globally ground-breaking innovative product in inflammation and immunology, and a crucial part of its dermatology strategic planning in China. The launch of this inhibitor marks a globally synchronized R&D and regulatory application process and